| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| P P Gleason, R L Conigliar. Neuroleptic malignant syndrome with risperidone. Pharmacotherapy. vol 17. issue 3. 1997-07-15. PMID:9165568. |
risperidone, a benzisoxazole derivative antipsychotic, has high serotonin 5-ht2 receptor blockade and dose-related d2 receptor blockade. |
1997-07-15 |
2023-08-12 |
Not clear |
| D J Stein, C Bouwer, S Hawkridge, R A Emsle. Risperidone augmentation of serotonin reuptake inhibitors in obsessive-compulsive and related disorders. The Journal of clinical psychiatry. vol 58. issue 3. 1997-04-28. PMID:9108814. |
risperidone augmentation of serotonin reuptake inhibitors in obsessive-compulsive and related disorders. |
1997-04-28 |
2023-08-12 |
Not clear |
| D J Stein, C Bouwer, S Hawkridge, R A Emsle. Risperidone augmentation of serotonin reuptake inhibitors in obsessive-compulsive and related disorders. The Journal of clinical psychiatry. vol 58. issue 3. 1997-04-28. PMID:9108814. |
indeed, augmentation of serotonin reuptake inhibitors with the atypical neuroleptic risperidone has been suggested to be useful in obsessive-compulsive disorder (ocd). |
1997-04-28 |
2023-08-12 |
Not clear |
| R A Littrell, M Schneiderha. The neurobiology of schizophrenia. Pharmacotherapy. vol 16. issue 6 Pt 2. 1997-03-04. PMID:8947997. |
these findings are supported by the recent development of new, effective antipsychotic agents, such as clozapine and risperidone, whose actions are attributed to their combined serotonin and dopamine antagonism. |
1997-03-04 |
2023-08-12 |
Not clear |
| J A Terró. The relaxant 5-HT receptor in the dog coronary artery smooth muscle: pharmacological resemblance to the cloned 5-ht7 receptor subtype. British journal of pharmacology. vol 118. issue 6. 1997-02-06. PMID:8832067. |
in gr127935-treated preparations, methiothepin (3 nm) and mianserin (1 microm), as well as the antipsychotics, clozapine (1 microm), pimozide (300 nm), risperidone (3 nm) and spiperone (1 microm), failed to induce a significant relaxation in prostaglandin f2x-precontracted vessels, but produced significant rightward displacements of the concentration-response curves to 5-ht and 5-ct without significantly reducing the emax. |
1997-02-06 |
2023-08-12 |
dog |
| P Hertel, G G Nomikos, M Iurlo, T H Svensso. Risperidone: regional effects in vivo on release and metabolism of dopamine and serotonin in the rat brain. Psychopharmacology. vol 124. issue 1-2. 1997-01-29. PMID:8935802. |
risperidone: regional effects in vivo on release and metabolism of dopamine and serotonin in the rat brain. |
1997-01-29 |
2023-08-12 |
rat |
| P Hertel, G G Nomikos, M Iurlo, T H Svensso. Risperidone: regional effects in vivo on release and metabolism of dopamine and serotonin in the rat brain. Psychopharmacology. vol 124. issue 1-2. 1997-01-29. PMID:8935802. |
the antipsychotic drug risperidone shows high affinity for both central serotonin (5-ht)2a and dopamine (da)-d2 receptors in vivo. |
1997-01-29 |
2023-08-12 |
rat |
| P Hertel, G G Nomikos, M Iurlo, T H Svensso. Risperidone: regional effects in vivo on release and metabolism of dopamine and serotonin in the rat brain. Psychopharmacology. vol 124. issue 1-2. 1997-01-29. PMID:8935802. |
by employing microdialysis in freely moving rats, the effects of acute risperidone administration on regional brain da and 5-ht release and metabolism were compared with the corresponding effects of the atypical antipsychotic drug clozapine as well as amperozide, the selective da-d2 receptor antagonist raclopride and the selective 5-ht2a/5-ht2c receptor antagonist ritanserin. |
1997-01-29 |
2023-08-12 |
rat |
| P Hertel, G G Nomikos, M Iurlo, T H Svensso. Risperidone: regional effects in vivo on release and metabolism of dopamine and serotonin in the rat brain. Psychopharmacology. vol 124. issue 1-2. 1997-01-29. PMID:8935802. |
in contrast to the regionally rather homogenous activation of brain da systems caused by risperidone, the drug was found to enhance brain 5-ht metabolism preferentially in the mpc, as indicated by the elevated extracellular concentration of 5-hydroxyindoleacetic acid (5-hiaa) in this region. |
1997-01-29 |
2023-08-12 |
rat |
| P Hertel, G G Nomikos, M Iurlo, T H Svensso. Risperidone: regional effects in vivo on release and metabolism of dopamine and serotonin in the rat brain. Psychopharmacology. vol 124. issue 1-2. 1997-01-29. PMID:8935802. |
the preferential activation of 5-ht release and metabolism in frontal cortical areas might be of particular relevance for the ameliorating effect of risperidone on negative symptoms in schizophrenia, especially when associated with depression. |
1997-01-29 |
2023-08-12 |
rat |
| W Danie. Metabolism of psychotropic drugs: pharmacological and clinical relevance. Polish journal of pharmacology. vol 47. issue 5. 1996-11-27. PMID:8868127. |
selective serotonin reuptake inhibitors, risperidone, carbamazepine, benzodiazepines), but others display quite different (eg. |
1996-11-27 |
2023-08-12 |
Not clear |
| A Kagaya, N Motohashi, A Kugaya, T Yamaji, T Hayashi, Y Okamoto, H Shinno, M Takebayashi, Y Uchitomi, S Yamawak. Cyclic GMP generation mediated by 5-HT-2 receptors via nitric oxide-dependent pathway and its effect on the desensitization of 5-HT-2 receptors in C6 glioma cells. Journal of neural transmission. General section. vol 100. issue 1. 1996-09-26. PMID:8748661. |
5-ht enhanced cgmp generation, and risperidone and ketanserin potently blocked the response. |
1996-09-26 |
2023-08-12 |
Not clear |
| S Kapur, G Remingto. Serotonin-dopamine interaction and its relevance to schizophrenia. The American journal of psychiatry. vol 153. issue 4. 1996-04-24. PMID:8599393. |
the therapeutic success of clozapine and risperidone has focused attention on the interaction between serotonin and dopamine systems as an avenue for superior therapeutics in schizophrenia. |
1996-04-24 |
2023-08-12 |
Not clear |
| W Wan, D J Ennulat, B M Cohe. Acute administration of typical and atypical antipsychotic drugs induces distinctive patterns of Fos expression in the rat forebrain. Brain research. vol 688. issue 1-2. 1996-02-14. PMID:8542328. |
administration of single doses of a wide range of typical neuroleptic antipsychotic drugs (including the potent dopamine d2 antagonist haloperidol and the mixed monoamine antagonist chlorpromazine) and atypical antipsychotic drugs (including the weak dopamine d2 antagonists clozapine and thioridazine, the relatively pure d2 antagonist raclopride and the mixed d2 and serotonin s2 antagonist risperidone). |
1996-02-14 |
2023-08-12 |
rat |
| H He, J S Richardso. A pharmacological, pharmacokinetic and clinical overview of risperidone, a new antipsychotic that blocks serotonin 5-HT2 and dopamine D2 receptors. International clinical psychopharmacology. vol 10. issue 1. 1995-08-30. PMID:7542676. |
a pharmacological, pharmacokinetic and clinical overview of risperidone, a new antipsychotic that blocks serotonin 5-ht2 and dopamine d2 receptors. |
1995-08-30 |
2023-08-12 |
human |
| H He, J S Richardso. A pharmacological, pharmacokinetic and clinical overview of risperidone, a new antipsychotic that blocks serotonin 5-HT2 and dopamine D2 receptors. International clinical psychopharmacology. vol 10. issue 1. 1995-08-30. PMID:7542676. |
the clinical success of risperidone suggests that the development of compounds with selective affinity for 5-ht2 or other serotonin receptors may result in even further improvements in the pharmacotherapy of psychiatric disorders. |
1995-08-30 |
2023-08-12 |
human |
| L Farde, S Nyberg, G Oxenstierna, Y Nakashima, C Halldin, B Ericsso. Positron emission tomography studies on D2 and 5-HT2 receptor binding in risperidone-treated schizophrenic patients. Journal of clinical psychopharmacology. vol 15. issue 1 Suppl 1. 1995-05-31. PMID:7537284. |
risperidone is, accordingly, a suitable drug for the examination of the clinical benefit of combined serotonin and dopamine antagonism. |
1995-05-31 |
2023-08-12 |
Not clear |
| D Keega. Risperidone: neurochemical, pharmacologic and clinical properties of a new antipsychotic drug. Canadian journal of psychiatry. Revue canadienne de psychiatrie. vol 39. issue 9 Suppl 2. 1995-04-06. PMID:7533051. |
risperidone, a novel antipsychotic with high binding affinity for serotonin 5-ht2 and a lesser affinity for dopamine d2 receptors, is described and clinical studies are reviewed. |
1995-04-06 |
2023-08-12 |
Not clear |
| A A Megens, F H Awouters, A Schotte, T F Meert, C Dugovic, C J Niemegeers, J E Leyse. Survey on the pharmacodynamics of the new antipsychotic risperidone. Psychopharmacology. vol 114. issue 1. 1995-03-08. PMID:7531353. |
the primary action of risperidone is serotonin 5-ht2 receptor blockade as shown by displacement of radioligand binding (ki: 0.16 nm), activity on isolated tissues (ec50: 0.5 nm), and antagonism of peripherally (ed50: 0.0011 mg/kg) and centrally (ed50: 0.014 mg/kg) acting 5-ht2 receptor agonists in rats. |
1995-03-08 |
2023-08-12 |
rat |
| S Grant, A Fitto. Risperidone. A review of its pharmacology and therapeutic potential in the treatment of schizophrenia. Drugs. vol 48. issue 2. 1995-01-10. PMID:7527327. |
risperidone, a benzisoxazol derivative, is a novel antipsychotic agent which combines potent serotonin (5-hydroxytryptamine) 5-ht2 and dopamine d2 receptor antagonism. |
1995-01-10 |
2023-08-12 |
Not clear |